Amgen Inc. (NASDAQ: AMGN) is one of the world’s largest biotechnology companies, focused on innovative medicines for oncology, cardiovascular disease, inflammation, bone health, and rare diseases. The company is well known for products like Repatha, Prolia, Enbrel, and Otezla.
Current Stock Price
Amgen stock is currently trading around $329.59 after a recent market gain, although it remains below its 52-week high of $391.29.
Why Amgen is Strong
- Strong Revenue Growth: Amgen reported Q1 2026 revenue of $8.6 billion, beating analyst expectations.
- Earnings Beat: Adjusted EPS came in at $5.15, above forecasts.
- Obesity Drug Potential: Its experimental obesity drug MariTide is attracting major investor attention and could become a future growth catalyst.
Is Amgen a Good Investment?
Positive factors:
- Strong dividend stock with consistent cash flow
- Large biotech market presence
- Expanding pipeline in obesity and rare diseases
Risks:
- Patent expirations affecting older drugs
- Competition in biotech and obesity market
- Moderate growth compared with faster biotech companies
Future Outlook (2026)
Amgen looks more like a stable long-term healthcare investment rather than a high-growth tech-style stock. If MariTide succeeds, it could unlock stronger upside in the next few years.
Investment View:
- Long-term (1–3 years): Moderately Bullish
- Short-term (weeks/months): Stable to slightly volatile
Potential price target: $350–$380 if pipeline growth remains strong in 2026.
